Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,267,462,044.57, representing a year-on-year increase of 2.50%[4] - Net profit attributable to shareholders for the same period was CNY 220,789,398.54, reflecting a significant increase of 32.59% compared to the previous year[4] - Basic and diluted earnings per share were both CNY 0.33, up by 32.00% from the same period last year[4] - Operating profit for Q1 2024 was ¥274,176,089.32, representing a significant increase of 38.2% from ¥198,426,538.66 in Q1 2023[16] - Net profit for Q1 2024 was ¥220,789,398.54, up 32.6% from ¥166,520,090.53 in Q1 2023[16] - The company reported a total comprehensive income of ¥220,789,398.54 for Q1 2024, compared to ¥166,520,090.53 in Q1 2023, indicating a strong performance[18] Cash Flow - The net cash flow from operating activities reached CNY 296,176,607.65, marking a 40.66% increase year-on-year[4] - In Q1 2024, the company reported cash inflows from operating activities of approximately CNY 1.30 billion, an increase of 18.1% compared to CNY 1.10 billion in Q1 2023[20] - The net cash flow from operating activities was CNY 296.18 million, up 40.6% from CNY 210.56 million in the same period last year[20] - Cash paid for purchasing goods and services was CNY 725.37 million, an increase of 13.9% from CNY 636.66 million in Q1 2023[20] - The company reported cash outflows from operating activities totaling CNY 1.00 billion, compared to CNY 888.94 million in Q1 2023, reflecting a 12.5% increase[20] - The company’s cash flow from financing activities was positive at CNY 2.34 million, reflecting a stable financing environment[21] Assets and Liabilities - Total assets at the end of the reporting period amounted to CNY 9,588,071,408.95, an increase of 2.89% from the end of the previous year[4] - The company’s non-current assets totaled RMB 3,849,378,326.12, up from RMB 3,773,115,590.79, which is an increase of about 2.02%[14] - The total current liabilities increased to RMB 1,763,513,212.82 from RMB 1,726,592,238.62, reflecting a rise of approximately 2.13%[14] - Total liabilities rose to ¥1,833,602,661.60, an increase of 2.8% from ¥1,784,212,772.67 in the previous year[16] - Total equity attributable to shareholders increased to ¥7,754,468,747.35, up 2.9% from ¥7,534,508,778.17[16] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 53,184[8] - Shareholders' equity attributable to the parent company was CNY 7,754,468,747.35, up 2.92% compared to the previous year[4] Other Financial Metrics - Research and development expenses increased to ¥39,921,990.72, up 29% from ¥30,947,488.73 in the previous year[16] - Deferred income increased to ¥70,089,448.78 from ¥57,620,534.05, marking a growth of 21.5%[16] - Non-recurring gains and losses totaled CNY 10,437,631.55 for the quarter[5] - The company experienced a foreign exchange impact on cash and cash equivalents of CNY 5.07 million, compared to a negative impact of CNY -4.47 million in the previous year[21] - The company reported a significant increase in inventory, which stood at RMB 1,033,270,321.63, down from RMB 1,054,610,571.71, a decrease of about 2.02%[13]
山东药玻(600529) - 2024 Q1 - 季度财报